Moderna's shares have seen a surge due to Canadian demand for the Covid vaccine. The company's mRNA-1083 is being compared with Pfizer's dual-target mRNA vaccines for influenza and COVID-19. Expansion in manufacturing and regulatory approval suggest future growth for mRNA vaccines. However, the company's decision to back out of some mRNA vaccine deals, noted uncertain business environment, and cancellation of a plan to establish a mRNA plant in Japan imply concerns. Regulatory approval for Moderna's COVID-19 vaccine and its updated version are significant achievements. However, cancellation of contracts by the U.S. for bird flu vaccine development has impacted the stock. In a positive milestone, Moderna's flu vaccine showed superior performance in trials, paving the way for a combination Covid shot. Despite setbacks such as withdrawal of a flu/COVID-19 combo vaccine candidate, Moderna continues to invest in research and development, advancing initiatives like mRNA-based bird flu vaccine and mRNA RSV vaccine. The company's role in quantum computing for modeling mRNA structure is noteworthy. Some concerns have emerged surrounding mRNA vaccine safety, with the FDA asking for more data for Moderna’s influenza COVID-19 combination vaccine.
Moderna MRNA News Analytics from Mon, 21 Oct 2024 07:00:00 GMT to Sat, 23 Aug 2025 06:45:00 GMT -
Rating 6
- Innovation 9
- Information 8
- Rumor 2
